For research use only.
Catalog No.S4029 Synonyms: Polymixin E Sulfate
CAS No. 1264-72-8
Colistin (Polymixin E) is a cyclic cationic decapeptide linked to a fatty acid side chain, it belongs to a group of similarly structured bacterial antimicrobial peptides.
Purity & Quality Control
Choose Selective Bacterial Inhibitors
|Description||Colistin (Polymixin E) is a cyclic cationic decapeptide linked to a fatty acid side chain, it belongs to a group of similarly structured bacterial antimicrobial peptides.|
Colistin (2 μg/mL) is active against most strains of Escherichia coli and P. aeruginosa, and all species of Enterobacter, Salmonella, Shigella, Pasteurella, Brucella, and Bordetella. Proteus, Serratia, Providencia. Colistin inhibits 225 strains of P.aeruginosa with MIC90 and MIC50 of 6.3 μg/mL and 1.6μg/mL, respectively. Colistin sulfate is approved only for topical and oral use because of its toxicity.  Colistin sulfate is administered orally (tablets or syrup) for bowel decontamination and topically as a powder for the treatment of bacterial skin infections. Colistin interacts with the bacterial membrane through electrostatic interactions between the cationic polypeptide (colistin) and anionic lipopolysaccharide (LPS) molecules in the outer membrane of the gram-negative bacteria, leading to derangement of the cell membrane. Colistin displaces magnesium (Mg+2) and calcium (Ca+2), which normally stabilize the LPS molecules, from the negatively charged LPS, leading to a local disturbance of the outer membrane. Colistin has also potent anti-endotoxin activity.  Colistin sulfate produces a strong postantibiotic effects against Acinetobacter baumannii ranging from 2.5 hours to 7.0 hours in a concentration-dependent manner. 
|In vivo||Colistin sulfate (5%, i.m.) causes the muscle circumference to appear erythematic in mice. Colistin sulfate (i.m., 15 mg/kg/day for 5 days) causes obvious neurotoxicity to piglets with moderate granular degenerations in the epithelial tissues from kidney and liver of mice. Colistin sulfate (i.m.) at dose of 2.5 mg/kg and 5.0 mg/kg results in Cmax of 3.73 mg/mL and 6.40 mg/mL, Tmax of 32 min and 34 min, t(1/2beta) of 256 min and 264 min, and absolute bioavailability of 95.94% and 88.45% in mice. |
|In vitro||Water||100 mg/mL|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Synonyms||Polymixin E Sulfate|
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04775238||Recruiting||Other: Silver nanoparticles|Other: Copper nanoparticles||Nosocomial Infections||Sohag University||February 27 2021||Not Applicable|
|NCT04208945||Recruiting||Drug: Colistin||Pneumonia Ventilator-associated|Gram-Negative Pneumonia||University of Thessaly||December 2019||Not Applicable|
|NCT03971877||Recruiting||Diagnostic Test: Rapid Polymyxin NP test||Colistin Resistance in Bacteria||University Hospital Bordeaux||December 16 2019||--|
|NCT04489459||Recruiting||Drug: Colistin|Drug: Meropenem|Drug: Tigecycline||Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae||Al-Azhar University||September 21 2019||Phase 4|
|NCT03597841||Completed||Drug: Combination therapy||Klebsiella Pneumonia|Bacteremia||Koç University||June 25 2018||--|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.